Screener / SEC EDGAR /CIK 0001515673 /10-K filed Feb 18, 2026, compared with Feb 19, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Ultragenyx Pharmaceutical Inc. RARE

Compare with peers Embed
Why it changed

The biggest changes in the 10-K filed Feb 18, 2026, in management's words

10-K, Item 7

This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Operating margin

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

-95.7% to -79.5% (+16.2 pts)

“for other research and development expenses, a decrease primarily due to decreased staffing and cost efficiencies to support internal manufacturing, and administrative and general support.”

Read it in the 10-K

Revenue

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+20.2%

“The increase in revenue was driven by higher demand for our approved products.”

Read it in the 10-K

“This increase in Crysvita revenue was primarily due to an increase in the number of patients on therapy.”

Read it in the 10-K

What management said, year by year

The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)

Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.

Revenue

2 of 2 years explained
  • FY 2025 +20.2%

    “The increase in revenue was driven by higher demand for our approved products.”

    Read it in the FY 2025 10-K

    “This increase in Crysvita revenue was primarily due to an increase in the number of patients on therapy.”

    Read it in the FY 2025 10-K
  • FY 2024 +29.0%

    “The increase in revenue was driven by higher demand for our approved products.”

    Read it in the FY 2024 10-K

    “Our Crysvita royalty revenue and collaboration revenue in the Profit-Share Territory increased by a net $22.5 million for the year ended December 31, 2024, compared to the same period in 2023; this increase in Crysvita revenue is primarily due to an increase in the number of patients on therapy.”

    Read it in the FY 2024 10-K

Operating margin

2 of 2 years explained
  • FY 2025 +16.2 pts

    “for other research and development expenses, a decrease primarily due to decreased staffing and cost efficiencies to support internal manufacturing, and administrative and general support.”

    Read it in the FY 2025 10-K
  • FY 2024 +35.4 pts

    “for other research and development expenses, an increase of $1.2 million, primarily related to increased staffing to support internal manufacturing, and administrative and general support.”

    Read it in the FY 2024 10-K

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K

Sources

The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.

Also

Financials: the numbers year by year.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RARE/export.csv") into a cell.

Next:Accounting checks
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.